Surrozen, Inc./DE Financing Cash Flow
Surrozen, Inc./DE (SRZN) reported Financing Cash Flow of $32.79 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-06
- Surrozen, Inc./DE net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $2.51M.
- Surrozen, Inc./DE net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $30.28M, a 60.36% decline year-over-year.
- Surrozen, Inc./DE net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $13.78M, a 15043.96% increase year-over-year.
- Surrozen, Inc./DE net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $9.00K.
- Surrozen, Inc./DE net cash provided by (used in) financing activities for fiscal 2025 was $85.05M, a 425.79% increase from fiscal 2024.
- Surrozen, Inc./DE net cash provided by (used in) financing activities for fiscal 2024 was $16.18M, a 5760.87% increase from fiscal 2023.
- Surrozen, Inc./DE net cash provided by (used in) financing activities for fiscal 2023 was $276.00K.
- Surrozen, Inc./DE net cash provided by (used in) financing activities for fiscal 2022 was -$2.56M, a 102.06% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 4 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $2.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $32.79M 10-Q · filed 2026-08-06 | $46.57M derived: sum of 3 quarters · filed 2026-08-06 | $46.58M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $30.28M 10-Q · filed 2026-05-06 | $44.06M derived: sum of 2 quarters · filed 2026-05-06 | $44.07M derived: sum of 3 quarters · filed 2026-05-06 | $38.95M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $13.78M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $13.79M derived: sum of 2 quarters · filed 2026-03-23 | $8.67M derived: sum of 3 quarters · filed 2026-08-06 | $85.05M 10-K · filed 2026-03-23 | |
| 2025-09-30 | $9.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | -$5.12M derived: sum of 2 quarters · filed 2026-08-06 | $71.27M 10-Q · filed 2025-11-07 | $71.36M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | -$5.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $71.26M 10-Q · filed 2026-08-06 | $71.35M derived: sum of 3 quarters · filed 2026-08-06 | $71.35M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $76.39M 10-Q · filed 2026-05-06 | $76.48M derived: sum of 2 quarters · filed 2026-05-06 | $76.48M derived: sum of 3 quarters · filed 2026-05-06 | $92.56M derived: sum of 4 quarters · filed 2026-05-06 | |
| 2024-12-31 | $91.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | $90.00K derived: sum of 2 quarters · filed 2026-03-23 | $16.18M derived: sum of 3 quarters · filed 2026-03-23 | $16.18M 10-K · filed 2026-03-23 | |
| 2024-09-30 | -$1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07 | $16.09M derived: sum of 2 quarters · filed 2025-11-07 | $16.09M 10-Q · filed 2025-11-07 | $16.23M derived: sum of 4 quarters · filed 2025-11-07 | |
| 2024-06-30 | $16.09M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | $16.09M 10-Q · filed 2025-08-08 | $16.23M derived: sum of 3 quarters · filed 2025-08-08 | $16.21M derived: sum of 4 quarters · filed 2025-08-08 | |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-09 | $141.00K derived: sum of 2 quarters · filed 2025-05-09 | $128.00K derived: sum of 3 quarters · filed 2025-05-09 | $315.00K derived: sum of 4 quarters · filed 2025-05-09 | |
| 2023-12-31 | $141.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $128.00K derived: sum of 2 quarters · filed 2025-03-31 | $315.00K derived: sum of 3 quarters · filed 2025-03-31 | $276.00K 10-K · filed 2025-03-31 | |
| 2023-09-30 | -$13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $174.00K derived: sum of 2 quarters · filed 2024-11-06 | $135.00K 10-Q · filed 2024-11-06 | -$2.41M derived: sum of 4 quarters · filed 2024-11-06 | |
| 2023-06-30 | $187.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $148.00K 10-Q · filed 2024-08-12 | -$2.40M derived: sum of 3 quarters · filed 2024-08-12 | -$2.41M derived: sum of 4 quarters · filed 2024-08-12 | |
| 2023-03-31 | -$39.00K 10-Q · filed 2024-05-08 | -$2.59M derived: sum of 2 quarters · filed 2024-05-08 | -$2.60M derived: sum of 3 quarters · filed 2024-05-08 | -$2.60M derived: sum of 4 quarters · filed 2024-05-08 | |
| 2022-12-31 | -$2.55M derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-10 | -$2.56M derived: sum of 2 quarters · filed 2024-04-10 | -$2.56M derived: sum of 3 quarters · filed 2024-04-10 | -$2.56M 10-K · filed 2024-04-10 | |
| 2022-09-30 | -$13.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | -$16.00K derived: sum of 2 quarters · filed 2023-11-08 | -$16.00K 10-Q · filed 2023-11-08 | $143.00K derived: sum of 4 quarters · filed 2023-11-08 | |
| 2022-06-30 | -$3.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | -$3.00K 10-Q · filed 2023-08-09 | $156.00K derived: sum of 3 quarters · filed 2023-08-09 | $124.75M derived: sum of 4 quarters · filed 2023-08-09 | |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-10 | $159.00K derived: sum of 2 quarters · filed 2023-05-10 | $124.75M derived: sum of 3 quarters · filed 2023-05-10 | $124.43M derived: sum of 4 quarters · filed 2023-05-10 | |
| 2021-12-31 | $159.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $124.75M derived: sum of 2 quarters · filed 2023-03-31 | $124.43M derived: sum of 3 quarters · filed 2023-03-31 | $124.63M 10-K · filed 2023-03-31 | |
| 2021-09-30 | $124.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $124.28M derived: sum of 2 quarters · filed 2022-11-14 | $124.47M 10-Q · filed 2022-11-14 | $124.53M derived: sum of 4 quarters · filed 2022-11-14 | |
| 2021-06-30 | -$314.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$118.00K 10-Q · filed 2022-08-11 | -$58.00K derived: sum of 3 quarters · filed 2022-08-11 | ||
| 2021-03-31 | $196.00K 10-Q · filed 2022-05-11 | $256.00K derived: sum of 2 quarters · filed 2022-05-11 | |||
| 2020-12-31 | $60.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $93.92M 10-K/A · filed 2021-05-14 | $50.05M 10-K · filed 2022-03-28 | ||
| 2020-09-30 | $49.99M 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B |